DCT

1:26-cv-21512

GlaxoSmithKline IP Development Ltd v. Transpire Bio Inc

Log In
Key Events
Complaint
complaint Intelligence

I. Executive Summary and Procedural Information

  • Parties & Counsel:
  • Case Identification: 1:26-cv-21512, S.D. Fla., 03/06/2026
  • Venue Allegations: Venue is alleged to be proper as Defendant Transpire Bio Inc. is incorporated in Florida, resides in the judicial district, and has allegedly committed substantial acts giving rise to the claims within the district.
  • Core Dispute: Plaintiff alleges that Defendant's Abbreviated New Drug Application (ANDA) to market a generic version of the TRELEGY ELLIPTA inhalation product infringes five patents related to the drug's formulation, method of use, and the dry powder inhaler device itself.
  • Technical Context: The technology concerns a triple-therapy dry powder inhalation product for the maintenance treatment of Chronic Obstructive Pulmonary Disease (COPD) and asthma.
  • Key Procedural History: This action was initiated under the Hatch-Waxman Act following Defendant's submission of ANDA No. 220811 and its subsequent notice letter to Plaintiff. The complaint states that its filing within the statutory 45-day window entitles Plaintiff to a 30-month stay of FDA approval for the accused generic product. The asserted patents are listed in the FDA's "Orange Book" for the TRELEGY ELLIPTA product. The complaint also notes a prior, separate litigation between the parties in the same district.

I. Case Timeline

Date Event
2005-07-28 U.S. Patent No. 8,746,242 Earliest Priority Date
2005-12-12 U.S. Patent No. 8,534,281 Earliest Priority Date
2009-12-01 U.S. Patent No. 9,750,726 Earliest Priority Date
2009-12-01 U.S. Patent No. 11,090,294 Earliest Priority Date
2009-12-01 U.S. Patent No. 12,396,986 Earliest Priority Date
2013-09-17 U.S. Patent No. 8,534,281 Issued
2014-06-10 U.S. Patent No. 8,746,242 Issued
2017-09-05 U.S. Patent No. 9,750,726 Issued
2017-09-18 FDA Approval of TRELEGY ELLIPTA
2021-08-17 U.S. Patent No. 11,090,294 Issued
2025-08-26 U.S. Patent No. 12,396,986 Issued
2025-11-21 Prior litigation mentioned in complaint
2026-01-21 Defendant's Notice Letter Date
2026-03-06 Complaint Filing Date

II. Technology and Patent(s)-in-Suit Analysis

I. U.S. Patent No. 8,534,281, "Manifold For Use In Medicament Dispenser," issued September 17, 2013

I. The Invention Explained

  • Problem Addressed: The patent background describes the technical challenge of ensuring effective liberation of dry powder medicament from a blister pack within an inhaler ʼ281 Patent, col. 1:29-37 A key goal is to improve the "fine particle fraction" of the delivered dose by promoting the de-aggregation of the powdered medicament as it is transported to the mouthpiece ʼ281 Patent, col. 1:40-55
  • The Patented Solution: The invention is an inhaler manifold that splits the patient's inhaled airflow into two paths. A primary airflow entrains the medicament powder from an opened blister pocket and carries it into a chamber ʼ281 Patent, col. 2:10-16 A secondary "bleed airflow" is diverted from the main air inlet (the "chimney") through one or more "bleed holes" directly into the chamber. This secondary airflow is designed to "disruptively impact" the primary flow, creating turbulence that helps break apart clumps of medicament powder ʼ281 Patent, abstract ʼ281 Patent, col. 2:16-21
  • Technical Importance: This airflow-splitting design provides a mechanical means to improve the de-aggregation of the drug powder, which is critical for ensuring that a consistent and respirable dose reaches the patient's lungs Compl. ¶22

II. Key Claims at a Glance

  • The complaint asserts at least independent claim 1 Compl. ¶49
  • Essential elements of Claim 1 include:
    • A manifold for use in a medicament dispenser device for delivering powder from plural blister packs.
    • The manifold comprises a body defining a chimney (with a single inlet and plural exits) and a chamber (with plural inlets and an exit).
    • Chimney exits and chamber inlets are arranged in "plural pairings," with each pairing associated with a blister pack.
    • Within these pairings, the chimney exit and chamber inlet lie side-by-side to direct airflow through the open blister pocket to entrain the medicament.
    • One or more "bleed holes" are provided between the chimney and the chamber, allowing "bleed airflow" to be directed into the chamber to "disruptively impact the airflow that transports the entrained medicament powder."
  • The complaint does not explicitly reserve the right to assert dependent claims for this patent.

II. U.S. Patent No. 8,746,242, "Medicament Dispenser," issued June 10, 2014

I. The Invention Explained

  • Problem Addressed: The patent addresses the need for user-friendly and reliable operation of inhaler devices ʼ242 Patent, col. 1:19-21 A specific problem is preventing accidental actuation of the dosing mechanism, which could occur if a user partially opens the device (e.g., for cleaning) without intending to take a dose ʼ242 Patent, col. 1:55-63
  • The Patented Solution: The invention is a dispenser with a mouthpiece cover that moves sequentially through three distinct positions: 1) fully covered, 2) part-uncovered, and 3) fully uncovered ʼ242 Patent, abstract The dispenser's internal mechanism is designed so that the initial movement of the cover from the first to the second position does not actuate the dose-dispensing mechanism. Actuation only occurs upon "any further movement" from the second to the third position, ensuring that a dose is prepared only when the user fully commits to opening the device ʼ242 Patent, col. 2:42-51
  • Technical Importance: This three-position mechanism acts as a safety feature to prevent dose wastage and ensure patients do not inadvertently prepare multiple doses before inhalation Compl. ¶28

II. Key Claims at a Glance

  • The complaint asserts at least independent claim 1 Compl. ¶66
  • Essential elements of Claim 1 include:
    • A medicament dispenser for use with a carrier holding multiple distinct medicament portions.
    • The dispenser comprises a dispensing mechanism, a mouthpiece, and a movable cover for the mouthpiece.
    • The cover is movable sequentially from a first (covered) position, to a second (part-uncovered) position, to a third (uncovered) position.
    • The cover couples with the dispensing mechanism such that movement from the first to the second position does not actuate the mechanism, but further movement from the second to the third position does result in actuation.
  • The complaint does not explicitly reserve the right to assert dependent claims for this patent.

III. U.S. Patent No. 9,750,726, "Combinations Of A Muscarinic Receptor Antagonist And A Beta-2 Adrenoreceptor Agonist," issued September 5, 2017

  • Technology Synopsis: This patent claims pharmaceutical combination products for treating respiratory diseases like COPD and asthma ʼ726 Patent, col. 1:20-27 The invention covers specific combinations of active pharmaceutical ingredients, including a dual therapy of umeclidinium and vilanterol, and a triple therapy that also includes fluticasone furoate, formulated as a dry powder for inhalation Compl. ¶31 ʼ726 Patent, abstract
  • Asserted Claims: At least claim 12 is asserted Compl. ¶82
  • Accused Features: The complaint alleges that Defendant's proposed generic product contains the same three active ingredients (fluticasone furoate, umeclidinium bromide, and vilanterol trifenatate) in the same dosage amounts as GSK's TRELEGY ELLIPTA, thereby infringing the claimed composition Compl. ¶82 Compl. ¶84

IV. U.S. Patent No. 11,090,294, "Combinations Of A Muscarinic Receptor Antagonist And A Beta-2 Adrenoreceptor Agonist," issued August 17, 2021

  • Technology Synopsis: This patent claims a method of treating chronic obstructive pulmonary disease (COPD) in a human ʼ294 Patent, col. 18:2-4 The claimed method comprises the once-per-day administration of a pharmaceutical combination product that includes specific chemical compounds corresponding to umeclidinium and vilanterol Compl. ¶35 Dependent claims add a third active ingredient, fluticasone furoate Compl. ¶111
  • Asserted Claims: At least claims 1 and 12 are asserted Compl. ¶101
  • Accused Features: The complaint alleges that Defendant's proposed generic product contains the claimed active ingredients and that its proposed labeling will instruct clinicians and patients to administer it once per day for the treatment of COPD, thereby inducing infringement of the claimed method Compl. ¶105 Compl. ¶106

V. U.S. Patent No. 12,396,986, "Combinations Of A Muscarinic Receptor Antagonist And A B-2 Adrenoreceptor Agonist," issued August 26, 2025

  • Technology Synopsis: This patent, like the ʼ726 patent, claims a pharmaceutical combination product. The claims cover a dry powder product comprising specific chemical compounds corresponding to umeclidinium and vilanterol, suitable for once-daily administration Compl. ¶39 Dependent claims further specify the chemical identities of the compounds and add fluticasone furoate to the combination Compl. ¶¶135-149
  • Asserted Claims: At least claims 1, 2, 3, 5, and 14 are asserted Compl. ¶121
  • Accused Features: The complaint alleges that Defendant's proposed generic product is a pharmaceutical combination product containing the same active ingredients as claimed, infringing the patent Compl. ¶121 Compl. ¶124

III. The Accused Instrumentality

I. Product Identification

The accused instrumentality is the proposed generic version of GSK's TRELEGY ELLIPTA drug product, as described in Defendant Transpire Bio Inc.'s ANDA No. 220811 Compl. ¶3 Compl. ¶42

II. Functionality and Market Context

  • The accused product is a dry powder for oral inhalation intended for the maintenance treatment of COPD and asthma Compl. ¶2 Compl. ¶105 It is a combination drug product containing three active ingredients: 100 mcg/inhalation of fluticasone furoate, 62.5 mcg/inhalation of umeclidinium bromide, and 25 mcg/inhalation of vilanterol trifenatate Compl. ¶42
  • The complaint alleges, upon information and belief, that the product will be administered using a dry powder inhaler device Compl. ¶51 The complaint references Defendant's website, which allegedly discloses delivery "platforms" including "dry-powder inhalers" and depicts inhaler devices and the manufacture of medicament blister packs Compl. ¶51 Compl. ¶53 One such device depicted is the "RollingstarTM dry powder inhaler" Compl. ¶70 The complaint alleges that this proposed generic product is bioequivalent to TRELEGY ELLIPTA and will be marketed as a generic version of it Compl. ¶43 Compl. ¶86

IV. Analysis of Infringement Allegations

I. '281 Patent Infringement Allegations

Claim Element (from Independent Claim 1) Alleged Infringing Functionality Complaint Citation Patent Citation
A manifold for use in a medicament dispenser device for the delivery of medicament powder from an open blister pocket of each of plural blister packs, the manifold comprising a body, Defendant's proposed generic version of TRELEGY ELLIPTA allegedly has a manifold for delivering medicament powder from plural blister packs. ¶53 col. 2:1-4
said body defining a chimney having only a single chimney inlet and plural chimney exits for directing airflow from said chimney inlet to said chimney exits; The manifold body allegedly defines a chimney with a single inlet and plural exits to direct airflow. ¶55 col. 2:5-9
the body further defining a chamber having plural chamber inlets and a chamber exit, The manifold body allegedly further defines a chamber with plural inlets and an exit. ¶56 col. 2:9-10
wherein the chimney exits and chamber inlets are arranged to form plural pairings of chimney exit and chamber inlet, each said pairing in use associated with an open blister pocket of a different one of said plural blister packs; The manifold allegedly has chimney exits and chamber inlets arranged in plural pairings, with each associated with a different open blister pocket. ¶57 col. 2:10-14
wherein the chimney exit and chamber inlet of the plural pairings lie side-by-side each other such that when said open blister pocket of the associated blister packs are positioned adjacent thereto said airflow is directed from chimney exit to chamber inlet via the associated open blister pockets to entrain said medicament powder... The chimney exits and chamber inlets allegedly lie side-by-side, directing airflow through the open blister pockets to entrain the powder. ¶58 col. 2:49-56
and wherein one or more bleed holes are provided between the chimney and the chamber such that bleed airflow is able to be directed into the chamber to disruptively impact the airflow that transports the entrained medicament powder. One or more bleed holes are allegedly provided between the chimney and the chamber to direct bleed airflow into the chamber to disruptively impact the main airflow. ¶58 col. 2:16-21

I. Identified Points of Contention

  • Evidentiary Questions: The complaint's allegations regarding the structure of the accused inhaler are made "upon information and belief" Compl. ¶¶53-58 A central point of contention will be an evidentiary one: what evidence will Plaintiff provide to demonstrate that Defendant's inhaler device in fact contains a manifold, chimney, chamber, and "bleed holes" that operate in the specific manner required by Claim 1?
  • Scope Questions: The meaning of the functional limitation "to disruptively impact the airflow" may be a key issue for claim construction. The question will be whether any airflow mixing within the chamber meets this limitation, or if a more specific type of turbulent interaction is required, raising the possibility that Defendant's device may operate differently.

II. '242 Patent Infringement Allegations

Claim Element (from Independent Claim 1) Alleged Infringing Functionality Complaint Citation Patent Citation
A medicament dispenser for use with at least one medicament carrier carrying multiple distinct medicament portions, said medicament dispenser comprising (a) a dispensing mechanism actuable for dispensing the distinct medicament portions... The accused inhaler device allegedly is a medicament dispenser with a dispensing mechanism for dispensing distinct medicaments carried by at least one carrier. ¶70; ¶71 col. 2:38-41
(b) a mouthpiece; and The accused dispenser allegedly includes a mouthpiece. ¶72 col. 2:41-42
(c) a cover for said mouthpiece, said cover being movably mounted to the dispenser for sequential movement from a first position, in which said mouthpiece is covered, to a second position, in which said mouthpiece is part-uncovered, to a third position in which said mouthpiece is uncovered; The accused dispenser allegedly has a cover for the mouthpiece that is movably mounted for sequential movement from a covered, to a part-uncovered, to a fully uncovered position. ¶73 col. 2:42-47
wherein said cover is adapted to couple with said dispensing mechanism such that movement of the cover from the first position to the second position does not result in actuation of the dispensing mechanism, but any further movement of the cover from the second position to the third position results in actuation of the dispensing mechanism. The cover of the accused dispenser is allegedly adapted to couple with the dispensing mechanism such that actuation does not occur when moving from the first to the second position, but does occur upon further movement from the second to the third position. ¶74 col. 2:47-51

I. Identified Points of Contention

  • Technical Questions: The allegations are based on "information and belief" and supported by references to exhibits depicting inhalers (Compl. ¶¶72-74). A primary technical question is whether the accused inhaler's cover and dispensing mechanism function as claimed. What evidence does the complaint provide that the accused device's cover operates with the specific three-position, delayed-actuation sequence required by Claim 1, as opposed to a different mechanical action?
  • Scope Questions: The term "actuation" could be a focus of dispute. The question may arise as to what degree of mechanical engagement or movement of the dispensing mechanism constitutes "actuation." A dispute could center on whether any preparatory movement of the mechanism during the first-to-second cover motion falls within the claim's negative limitation ("does not result in actuation").

V. Key Claim Terms for Construction

  • Term: "to disruptively impact the airflow" (from '281 Patent, Claim 1)

    • Context and Importance: This term defines the function of the "bleed airflow." The infringement analysis will depend heavily on whether the interaction between airflows in the accused device meets this functional requirement. Practitioners may focus on this term because it is qualitative and its scope will determine whether simple air mixing infringes, or if a more specific, turbulent, or forceful interaction is necessary.
    • Intrinsic Evidence for Interpretation:
      • Evidence for a Broader Interpretation: The patent abstract states the purpose is to "promote break up" of the powder, suggesting any interaction that achieves this goal could be considered a "disruptive impact" ʼ281 Patent, abstract
      • Evidence for a Narrower Interpretation: The specification describes creating "regions of high shear" and causing particles to "collide with said wall," which could support a narrower construction requiring a specific type of turbulent or forceful interaction rather than simple mixing ʼ281 Patent, col. 6:60-64

  • Term: "actuation of the dispensing mechanism" (from '242 Patent, Claim 1)

    • Context and Importance: This term is central to the patent's safety feature, which delays the "actuation" step. The case may turn on whether any movement of the dispenser's internal gearing during the initial opening of the cover constitutes "actuation." Practitioners may focus on this term because if "actuation" is construed broadly to mean any movement of the dispensing gears, it may be easier for the Defendant to argue non-infringement.
    • Intrinsic Evidence for Interpretation:
      • Evidence for a Broader Interpretation: A defendant might argue that any engagement or partial movement of the gear train ʼ242 Patent, FIG. 5 constitutes "actuation," even if a dose is not fully prepared.
      • Evidence for a Narrower Interpretation: The claim language links "actuation" to a "result." The summary of the invention describes the outcome as making a "discrete dose of medicament... available" ʼ242 Patent, col. 2:33-35 This may support a narrower construction where "actuation" requires the full sequence of events that prepares a dose for inhalation, not merely intermediate mechanical movements.

VI. Other Allegations

  • Indirect Infringement: The complaint alleges both induced and contributory infringement for all five asserted patents Compl. ¶61 Compl. ¶77 Compl. ¶96 Compl. ¶116 Compl. ¶152 For the device patents ('281, '242), the basis is that the proposed generic product is allegedly "especially made or adapted for use in infringing" Compl. ¶60 Compl. ¶76 For the method of use patent ('294), the complaint alleges inducement based on the proposed labeling, which will allegedly instruct clinicians and patients to perform the claimed method of treating COPD Compl. ¶105 Compl. ¶115
  • Willful Infringement: The complaint alleges willful infringement for all five patents Compl. ¶63 Compl. ¶79 Compl. ¶98 Compl. ¶118 Compl. ¶154 The allegations are based on Defendant's alleged "actual and constructive knowledge" of the patents prior to its ANDA filing, with the filing itself constituting an act of infringement Compl. ¶59 Compl. ¶75 Compl. ¶94 Compl. ¶114 Compl. ¶150

VII. Analyst's Conclusion: Key Questions for the Case

  1. A central issue will be one of technical and evidentiary proof: For the device patents ('281 and '242), can GSK, through discovery and expert analysis, demonstrate that the accused generic inhaler-alleged to infringe based on "information and belief"-actually incorporates the specific manifold architecture and three-position cover mechanism required by the claims?
  2. A second core issue will be one of definitional scope: How will the court construe the functional term "disruptively impact" from the '281 patent? The case may turn on whether this requires a specific, high-shear turbulent effect, or if it can be read more broadly to cover general airflow mixing, which could expand the scope of infringement.
  3. Finally, for the composition and method of use patents ('726, '294, and '986), where the infringement allegation appears facially direct based on the ANDA filing, a key question will be patent validity: While not addressed in the complaint, the viability of these claims will likely depend on GSK's ability to defend them against invalidity challenges, such as obviousness, which are common defenses in ANDA litigation.